2. Anti-infection Cell Cycle/DNA Damage
  3. Bacterial G-quadruplex
  4. Antibiofilm agent-19

Antibiofilm agent-19 is an antibiofilm agent with iron-chelating activity. Antibiofilm agent-19 potently inhibits biofilm formation by wild-type PAO1 and the hyper-biofilm mutant strain PAO1-ΔwspF. Antibiofilm agent-19 promotes the formation of c-di-GMP G-quadruplexes and disrupts iron acquisition systems. It can be used in studies on antibacterial adjuvants.

For research use only. We do not sell to patients.

Antibiofilm agent-19

Antibiofilm agent-19 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Antibiofilm agent-19 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Antibiofilm agent-19 is an antibiofilm agent with iron-chelating activity. Antibiofilm agent-19 potently inhibits biofilm formation by wild-type PAO1 and the hyper-biofilm mutant strain PAO1-ΔwspF. Antibiofilm agent-19 promotes the formation of c-di-GMP G-quadruplexes and disrupts iron acquisition systems. It can be used in studies on antibacterial adjuvants[1].

In Vitro

Antibiofilm agent-19 (compound 11f) (0.156-2.5 μM; 24 h) potently inhibits biofilm formation by P. aeruginosa PAO1-ΔwspF (at 0.156 μM) and wild-type PAO1 (at 2.5 μM) without affecting bacterial growth[1].
Antibiofilm agent-19 (0-2.5 μM; 12-16 h) reduces the production of extracellular polymeric substances in P. aeruginosa, with the strongest efficacy observed in the PAO1-ΔwspF strain with high c-di-GMP levels[1].
Antibiofilm agent-19 (0.125-50 μM; 24 h) disrupts iron homeostasis in P. aeruginosa by promoting siderophore secretion, and this effect is reversed by the addition of excess Fe3+ [1].
Antibiofilm agent-19 (6.25-200 μM; 24 h) exhibits excellent biocompatibility, with no significant cytotoxicity against Vero cells or RAW264.7 macrophages even at concentrations as high as 200 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antibiofilm agent-19 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Vero cells, RAW264.7 macrophages
Concentration: 6.25, 12.5, 25, 50, 100 and 200 μM
Incubation Time: 24 h
Result: Resulted in >90% viability in both Vero cells and RAW264.7 macrophages across all tested concentrations, with no observable morphological alterations.
In Vivo

Antibiofilm agent-19 (0.156-2.5 μM; intracoelomic injection; single dose) with Tobramycin (HY-B0441) or Ciprofloxacin (HY-B0356) significantly increases the survival rate of Galleria mellonella during infection with P. aeruginosa PAO1/PAO1-ΔwspF[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Galleria mellonella infected with P. aeruginosa strains PAO1 (wild-type)[1]
Dosage: 2.5 μM (co-administered with Ciprofloxacin 0.001 mg/mL or Tobramycin 0.0025 mg/mL)
Administration: intracoelomic injection; single dose
Result: Achieved >70% larval survival at day 5 when co-administered with tobramycin, compared to 40% survival with tobramycin alone.
Achieved nearly 80% larval survival at day 5 when co-administered with ciprofloxacin, a statistically significant improvement over ciprofloxacin alone.
Animal Model: Galleria mellonella infected with P. aeruginosa strains PAO1-ΔwspF (high-biofilm mutant)[1]
Dosage: 0.156 μM (co-administered with Ciprofloxacin 0.001 mg/mL or Tobramycin 0.0025 mg/mL)
Administration: intracoelomic injection; single dose
Result: Significantly improved larval survival rates at day 5 when co-administered with either tobramycin or ciprofloxacin compared to the corresponding antibiotic alone.
Molecular Weight

484.35

Formula

C19H21IN2O3S
SMILES

C[N+]1=C(SC2=CC=CC=C21)/C=C/C(N(C=C3O)CCCOC)=CC3=O.[I-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Antibiofilm agent-19 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Antibiofilm agent-19Antibiofilm agent19Antibiofilm agent 19BacterialG-quadruplexc-di-GMP G-quadruplexVero cellstobramycinciprofloxacinbiofilmPseudomonas aeruginosaRAW264.7 macrophagesGalleria mellonellaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Antibiofilm agent-19
Cat. No.:
HY-181713
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.